

## Cedazuridine

## Chemical Properties

CAS No. : 1141397-80-9


Formula: C<sub>9</sub>H<sub>14</sub>F<sub>2</sub>N<sub>2</sub>O<sub>5</sub>

Molecular Weight: 268.21

Storage: Store at low temperature, Keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Cedazuridine ((4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahyouridine) is an oral inhibitor of cytidine deaminase with antineoplastic properties.
Targets(IC50)	Others, DNA Methyltransferase
In vivo	Oral Cedazuridine when combined with Azacitidine achieves successful tumor regression in both human cell line-derived xenograft transplantation experiment and patient-derived xenograft models[2].

## Solubility Information

Solubility	DMSO: 17.6 mg/mL (65.62 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 1.76 mg/mL (6.56 mM), Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	3.7284 mL	18.6421 mL	37.2842 mL
5 mM	0.7457 mL	3.7284 mL	7.4568 mL
10 mM	0.3728 mL	1.8642 mL	3.7284 mL
50 mM	0.0746 mL	0.3728 mL	0.7457 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Garcia-Manero G, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. *Blood*. 2020 Aug 6;136(6):674-683.
- Ramsey HE, et al. Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model. *Target Oncol*. 2020 Apr;15(2):231-240.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481